Drug Profile
Ordesekimab - Amgen
Alternative Names: AMG-714; Anti-IL-15 MAB; HuMax anti-IL15; HuMax-IL-15; MAb146B7; PRV-015Latest Information Update: 13 Feb 2024
Price :
$50
*
At a glance
- Originator Genmab
- Developer Amgen; Celimmune; Immune Tolerance Network; National Institute of Allergy and Infectious Diseases; Provention Bio
- Class Anti-inflammatories; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Interleukin 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coeliac disease; Vitiligo
- Discontinued Inflammation; Lymphoma; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 06 Feb 2024 Provention Bio completes the enrolment from its Phase-IIb PROACTIVE clinical trials in Coeliac disease in USA, Netherlands, Canada, Spain (SC) (NCT04424927)
- 27 Apr 2023 Provention Bio has been acquired by Sanofi
- 12 Apr 2023 Provention Bio has patent protection for Ordesekimab in USA, Europe and ex-US countries